Report Cover

Global Follicular Lymphoma Drugs Market Size, Status and Forecast 2021-2027


Global Follicular Lymphoma Drugs Scope and Market Size
Follicular Lymphoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Patient Age in terms of revenue and forecast for the period 2016-2027.

Segment by Type
    Chemotherapy Drug
    Monoclonal Antibody
    Kinase Inhibitor
    CAR T-cell Therapy
    Others

Segment by Patient Age
    < 55
    55-64
    65+

By Region
    North America
    Europe
    Japan
    China
    Southeast Asia
    India

By Company
    Genentech (Roche)
    Bristol-Myers Squibb
    Gilead Sciences
    TG Therapeutics
    Bayer
    Secura Bio
    Epizyme
    Jazz Pharmaceuticals
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (2021-2027)
        1.2.2 Chemotherapy Drug
        1.2.3 Monoclonal Antibody
        1.2.4 Kinase Inhibitor
        1.2.5 CAR T-cell Therapy
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Follicular Lymphoma Drugs Market Share by Patient Age (2021-2027)
        1.3.2 < 55
        1.3.3 55-64
        1.3.4 65+
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
    2.1 Global Follicular Lymphoma Drugs Market Size
     2.2 Follicular Lymphoma Drugs Market Size by Regions
        2.2.1 Follicular Lymphoma Drugs Growth Rate by Regions (2021-2027)
        2.2.2 Follicular Lymphoma Drugs Market Share by Regions (2021-2027)
    2.3 Industry Trends
        2.3.1 Market Top Trends
        2.3.2 Market Use Cases

3 Key Players
    3.1 Follicular Lymphoma Drugs Revenue by Players (2020-2021)
    3.2 Follicular Lymphoma Drugs Key Players Headquaters and Area Served
    3.3 Key Players Follicular Lymphoma Drugs Product/Solution/Service
    3.4 Date of Enter into Follicular Lymphoma Drugs Market
    3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown by Type and by Patient Age
    4.1 Global Follicular Lymphoma Drugs Market Size by Type (2021-2027)
    4.2 Global Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027)

5 North America
   5.1 North America Follicular Lymphoma Drugs Market Forecast (2021-2027)
    5.2 Follicular Lymphoma Drugs Key Players in North America
    5.3 North America Follicular Lymphoma Drugs Market Size by Type
    5.4 North America Follicular Lymphoma Drugs Market Size by Patient Age
        6.4.4 Canada

6 Europe
    6.1 Europe Follicular Lymphoma Drugs Market Forecast (2021-2027)
    6.2 Follicular Lymphoma Drugs Key Players in Europe
    6.3 Europe Follicular Lymphoma Drugs Market Size by Type
    6.4 Europe Follicular Lymphoma Drugs Market Size by Patient Age

7 Japan
    7.1 Japan Follicular Lymphoma Drugs Market Forecast (2021-2027)
    7.2 Follicular Lymphoma Drugs Key Players in Europe
    7.3 Japan Follicular Lymphoma Drugs Market Size by Type
    7.4 Japan Follicular Lymphoma Drugs Market Size by Patient Age

8 Rest of World
    8.1 China
        8.1.1 China Follicular Lymphoma Drugs Market Analysis
        8.1.2 Key Players in China
    8.2 Southeast Asia
        8.2.1 Southeast Asia Follicular Lymphoma Drugs Market Analysis
        8.2.2 Key Players in Southeast Asia
    8.3 India
        8.3.1 India Follicular Lymphoma Drugs Market Analysis
        8.3.2 Key Players in India


9 International Player Profiles
    9.1 Genentech (Roche)
        9.1.1 Genentech (Roche) Company Details
        9.1.2 Genentech (Roche) Description and Business Overview
        9.1.3 Genentech (Roche) Follicular Lymphoma Drugs Introduction
        9.1.4 Genentech (Roche) Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.1.5 Genentech (Roche) Recent Development
    9.2 Bristol-Myers Squibb
        9.2.1 Bristol-Myers Squibb Company Details
        9.2.2 Bristol-Myers Squibb Description and Business Overview
        9.2.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Introduction
        9.2.4 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.2.5 Bristol-Myers Squibb Recent Development
    9.3 Gilead Sciences
        9.3.1 Gilead Sciences Company Details
        9.3.2 Gilead Sciences Description and Business Overview
        9.3.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
        9.3.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.3.5 Gilead Sciences Recent Development
    9.4 TG Therapeutics
        9.4.1 TG Therapeutics Company Details
        9.4.2 TG Therapeutics Description and Business Overview
        9.4.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
        9.4.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.4.5 TG Therapeutics Recent Development
    9.5 Bayer
        9.5.1 Bayer Company Details
        9.5.2 Bayer Description and Business Overview
        9.5.3 Bayer Follicular Lymphoma Drugs Introduction
        9.5.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.5.5 Bayer Recent Development
    9.6 Secura Bio
        9.6.1 Secura Bio Company Details
        9.6.2 Secura Bio Description and Business Overview
        9.6.3 Secura Bio Follicular Lymphoma Drugs Introduction
        9.6.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.6.5 Secura Bio Recent Development
    9.7 Epizyme
        9.7.1 Epizyme Company Details
        9.7.2 Epizyme Description and Business Overview
        9.7.3 Epizyme Follicular Lymphoma Drugs Introduction
        9.7.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.7.5 Epizyme Recent Development
    9.8 Jazz Pharmaceuticals
        9.8.1 Jazz Pharmaceuticals Company Details
        9.8.2 Jazz Pharmaceuticals Description and Business Overview
        9.8.3 Jazz Pharmaceuticals Follicular Lymphoma Drugs Introduction
        9.8.4 Jazz Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2021)
        9.8.5 Jazz Pharmaceuticals Recent Development

10 Market Dynamics
    10.1 Industry Trends
    10.2 Market Drives
    10.3 Market Challenges
    10.4 Market Restraints

11 Key Findings in This Report
12 Appendix
    12.1 Research Methodology
        12.1.1 Methodology/Research Approach
        12.1.2 Data Source
    12.2 Disclaimer
    12.3 Author Details

List of Tables Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (2021-2027) (US$ Million) Table 2. Key Players of Chemotherapy Drug Table 3. Key Players of Monoclonal Antibody Table 4. Key Players of Kinase Inhibitor Table 5. Key Players of CAR T-cell Therapy Table 6. Key Players of Others Table 7. Global Follicular Lymphoma Drugs Market Size Growth by Patient Age (2021-2027) (US$ Million) Table 8. Global Follicular Lymphoma Drugs Market Size by Regions (2021-2027) (US$ Million) Table 9. Global Follicular Lymphoma Drugs Market Share by Regions (2021-2027) Table 10. Market Top Trends Table 11. Market Use Cases Table 12. Global Follicular Lymphoma Drugs Revenue by Players (2020-2021) (US$ Million) Table 13. Global Follicular Lymphoma Drugs Market Share by Players (2020-2021) Table 14. Key Players Headquarters and Area Served Table 15. Key Players Follicular Lymphoma Drugs Product Solution and Service Table 16. Date of Enter into Follicular Lymphoma Drugs Market Table 17. Mergers & Acquisitions, Expansion Plans Table 18. Global Follicular Lymphoma Drugs Market Size by Type (2021-2027) (US$ Million) Table 19. Global Follicular Lymphoma Drugs Market Size Share by Type (2021-2027) Table 20. Global Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027) (US$ Million) Table 21. Global Follicular Lymphoma Drugs Market Size Share by Patient Age (2021-2027) Table 22. North America Key Players Follicular Lymphoma Drugs Revenue (2020-2021) (US$ Million) Table 23. North America Key Players Follicular Lymphoma Drugs Market Share (2020-2021) Table 24. North America Follicular Lymphoma Drugs Market Size by Type (2021-2027) (US$ Million) Table 25. North America Follicular Lymphoma Drugs Market Share by Type (2021-2027) Table 26. North America Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027) (US$ Million) Table 27. North America Follicular Lymphoma Drugs Market Share by Patient Age (2021-2027) Table 28. Europe Key Players Follicular Lymphoma Drugs Revenue (2020-2021) (US$ Million) Table 29. Europe Key Players Follicular Lymphoma Drugs Market Share (2020-2021) Table 30. Europe Follicular Lymphoma Drugs Market Size by Type (2021-2027) (US$ Million) Table 31. Europe Follicular Lymphoma Drugs Market Share by Type (2021-2027) Table 32. Europe Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027) (US$ Million) Table 33. Europe Follicular Lymphoma Drugs Market Share by Patient Age (2021-2027) Table 34. Japan Key Players Follicular Lymphoma Drugs Revenue (2020-2021) (US$ Million) Table 35. Japan Key Players Follicular Lymphoma Drugs Market Share (2020-2021) Table 36. Japan Follicular Lymphoma Drugs Market Size by Type (2021-2027) (US$ Million) Table 37. Japan Follicular Lymphoma Drugs Market Share by Type (2021-2027) Table 38. Japan Follicular Lymphoma Drugs Market Size by Patient Age (2021-2027) (US$ Million) Table 39. Japan Follicular Lymphoma Drugs Market Share by Patient Age (2021-2027) Table 40. Key Players in China Table 41. Key Players in Southeast Asia Table 42. Key Players in India Table 43. Genentech (Roche) Company Details Table 44. Genentech (Roche) Description and Business Overview Table 45. Genentech (Roche) Follicular Lymphoma Drugs Product Table 46. Genentech (Roche) Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 47. Genentech (Roche) Recent Development Table 48. Bristol-Myers Squibb Company Details Table 49. Bristol-Myers Squibb Description and Business Overview Table 50. Bristol-Myers Squibb Follicular Lymphoma Drugs Product Table 51. Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 52. Bristol-Myers Squibb Recent Development Table 53. Gilead Sciences Company Details Table 54. Gilead Sciences Description and Business Overview Table 55. Gilead Sciences Follicular Lymphoma Drugs Product Table 56. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 57. Gilead Sciences Recent Development Table 58. TG Therapeutics Company Details Table 59. TG Therapeutics Description and Business Overview Table 60. TG Therapeutics Follicular Lymphoma Drugs Product Table 61. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 62. TG Therapeutics Recent Development Table 63. Bayer Company Details Table 64. Bayer Description and Business Overview Table 65. Bayer Follicular Lymphoma Drugs Product Table 66. Bayer Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 67. Bayer Recent Development Table 68. Secura Bio Company Details Table 69. Secura Bio Description and Business Overview Table 70. Secura Bio Follicular Lymphoma Drugs Product Table 71. Secura Bio Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 72. Secura Bio Recent Development Table 73. Epizyme Company Details Table 74. Epizyme Description and Business Overview Table 75. Epizyme Follicular Lymphoma Drugs Product Table 76. Epizyme Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 77. Epizyme Recent Development Table 78. Jazz Pharmaceuticals Company Details Table 79. Jazz Pharmaceuticals Description and Business Overview Table 80. Jazz Pharmaceuticals Follicular Lymphoma Drugs Product Table 81. Jazz Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business 2020 and 2021 Table 82. Jazz Pharmaceuticals Recent Development Table 83. Follicular Lymphoma Drugs Market Trends Table 84. Follicular Lymphoma Drugs Market Drivers Table 85. Follicular Lymphoma Drugs Market Challenges Table 86. Follicular Lymphoma Drugs Market Restraints Table 87. Research Programs/Design for This Report Table 88. Key Data Information from Secondary Sources Table 89. Key Data Information from Primary Sources List of Figures Figure 1. Global Follicular Lymphoma Drugs Market Share by Type in 2021 & 2027 Figure 2. Chemotherapy Drug Features Figure 3. Monoclonal Antibody Features Figure 4. Kinase Inhibitor Features Figure 5. CAR T-cell Therapy Features Figure 6. Others Features Figure 7. Global Follicular Lymphoma Drugs Market Share by Patient Age in 2021 & 2027 Figure 8. < 55 Case Studies Figure 9. 55-64 Case Studies Figure 10. 65+ Case Studies Figure 11. Follicular Lymphoma Drugs Report Years Considered Figure 12. Global Follicular Lymphoma Drugs Market Size and Growth Rate (2020-2027) (US$ Million) Figure 13. Global Follicular Lymphoma Drugs Market Share by Regions (2020-2027) Figure 14. Global Follicular Lymphoma Drugs Market Share by Players in 2021 Figure 15. Global Follicular Lymphoma Drugs Market Size Market Share by Type (2021-2027) Figure 16. Global Follicular Lymphoma Drugs Market Size Market Share by Patient Age (2021-2027) Figure 17. Global Follicular Lymphoma Drugs Revenue Market Share by Patient Age in 2021 Figure 18. North America Follicular Lymphoma Drugs Market Size 2021-2027 (US$ Million) Figure 19. Europe Follicular Lymphoma Drugs Market Size 2021-2027 (US$ Million) Figure 20. Japan Follicular Lymphoma Drugs Market Size 2021-2027 (US$ Million) Figure 21. Follicular Lymphoma Drugs Market Size in China (2021-2027) (US$ Million) Figure 22. Follicular Lymphoma Drugs Market Size in Southeast Asia (2021-2027) (US$ Million) Figure 23. Follicular Lymphoma Drugs Market Size in India (2021-2027) (US$ Million) Figure 24. Bottom-up and Top-down Approaches for This Report Figure 25. Data Triangulation Figure 26. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us